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Abstract
Background: Enteroviruses (EVs) are an important cause of illness, especially in neonates and young infants. Clinical
and laboratory findings at different ages, brain imaging, and outcomes have been inadequately investigated.
Methods: We retrospectively investigated EV infections occurring at an Italian tertiary care center during 2006–2017.
Cases were confirmed with a positive polymerase chain reaction on blood or cerebrospinal fluid. Clinical and laboratory
findings according to age at presentation were analyzed.
Results: Among 61 cases of EV infection, 56 had meningitis, 4 had encephalitis, and 1 had unspecific febrile illness. Forty-
seven cases (77.0%) presented at less than 1 year of age, and most were less than 90 days of age (n = 44). Presentation
with fever (p < 0.01), higher median temperature (p < 0.01), and irritability (p < 0.01) were significantly more common
among infants aged less than 90 days, who also had significantly higher peak temperatures during the course of the
disease (p < 0.01). In contrast, gastrointestinal symptoms were more common in infants and children aged over 90 days
(p = 0.02). Only 4 of 61 infections (6.5%) were severe and all affected younger infants (p < 0.01).
Conclusions: We detail epidemiological, clinical, and laboratory findings in a cohort of 61 children. Infants aged less than
90 days have more severe disease; they are more likely to present with fever, higher median temperature, and irritability
and less likely to develop gastrointestinal symptoms.
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Background
Enteroviruses (EVs) are small, single-stranded, positive
sense RNA viruses belonging to the family Picornaviri-
dae. Currently, more than 100 EV serotypes are known
to infect humans and have been classified into 4 species
(from A to D) [1]. EVs have a worldwide distribution
and show seasonal patterns of incidence [2]. EVs are pri-
marily transmitted from person to person via fecal-oral
or respiratory routes. The primary replication sites are
the epithelial cells of the oropharyngeal and intestinal mu-
cosa. A viremia may lead to secondary infections of the
central nervous system, myocardium, liver, and pleura [3].
Due to immaturity of the immune system, both the inci-
dence and severity of EV infections are higher among
younger infants. Risk factors in neonates include absence
of neutralizing antibodies to the specific infecting sero-
type, maternal illness prior to or at delivery, prematurity,
illness onset within the first few days of life, multi-organ
disease, severe hepatitis, and infecting serotype [4]. Al-
though infections in the pediatric population are mostly
asymptomatic, clinical manifestations may range from
minor febrile illnesses to severe, sometimes fatal condi-
tions, including aseptic meningitis, encephalitis, acute flac-
cid paralysis, myocarditis, and acute hepatitis [5–8]. The
polymerase chain reaction (PCR) represents the gold
standard for the diagnosis of EV infections [9], and helps
to reduce the length of stay and inappropriate antibiotic
use [10–12].
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Previous studies have reported the molecular epidemi-
ology of EV infections [13–15], but data regarding the
clinical presentation at different ages and their short-term
outcomes have not been investigated in detail. Further-
more, there are no recommendations for managing neo-
nates with confirmed EV infection, so that the decision to
perform accurate investigations (such as MRI or EEG) is
left to individual clinician. The aim of this study was to
define the burden and short-term outcome of EV infec-
tions in a cohort of children admitted to an Italian tertiary
care center. Furthermore, in order to define the clinical
spectrum and to assess whether patterns of disease may
vary according to age, we compared clinical and labora-
tory findings of cases aged less or more than 90 days.
Methods
Study design
This is a single center, retrospective cohort study of EV in-
fections carried out at Azienda Ospedaliero-Universitaria
Policlinico (Modena, Italy), a tertiary care center. This is a
pediatric referral hospital for the whole city, with approxi-
mately 3500 live births/year, 400 neonatal and 1600
pediatric admissions/year. The laboratory database was
searched for cases of positive EV-PCR in cerebrospinal
fluid (CSF) or plasma samples of children admitted to the
nursery, neonatal intensive care unit (NICU), and
pediatric units between January 2006 and December 2017.
Characteristics of each EV infection were recorded using a
standardized form. Details included maternal history, sex,
age at presentation, clinical symptoms, laboratory data,
catecholamine support, antibiotic therapies, length of stay,
imaging and outcomes. For neonates and infants, mater-
nal data (mode of delivery, breastfeeding) were also re-
corded. The project was approved by the local ethical
committee (No 4658/2017).
Virological methods
Nucleic acids were extracted from 1mL of CSF or plasma
by using NucliSENS EasyMAG instrument (bioMérieux,
Marcy l’Etoile, France) and submitted to amplification by
Real Time Reverse Transcriptase Polymerase Chain Reac-
tion for EVs. The sensitivity of the method was 10 copies/
reaction. The specificity was 100% for negative samples
whereas cross reactivity was absent (ELITechGroup, S.p.A,
Turin, Italy). Both sensitivity and specificity were evaluated
by external quality control as NEQAS and QCMD.
Definitions
Aseptic meningitis was a clinical state indicating menin-
gitis with a positive CSF EV-PCR (in absence of bacterial
pathogens).
Encephalitis was aseptic meningitis associated with re-
duced consciousness (lasting more than 24 h) and at
least 3 of the following: seizures, focal neurologic signs,
raised CSF white blood cell (WBC) count (defined as
≥20/μL, 0–30 days of life; ≥15/μL, 30–60 days of life; or ≥
5/μL, > 60 days of life) [16, 17], neuroimaging suggestive
of encephalitis, and abnormal electroencephalography
(EEG) consistent with encephalitis [18].
Hepatic necrosis with coagulopathy was associated
with aspartate transaminase or alanine transaminase > 3
times the upper limit of normal and platelet count <
100,000/μL, plus an abnormal coagulation profile [19].
Myocarditis was a positive CSF and/or plasma EV-PCR
plus an abnormal heart ultrasound study (ejection frac-
tion < 50%, signs of congestive heart failure), or in-
creased troponin I [20].
Severe infection included at least one of the following: en-
cephalitis, mechanical ventilation, catecholamine support.
Neurodevelopmental assessment
Neurodevelopmental assessment was performed in high-
risk patients (neonates with documented brain lesions on
magnetic resonance imaging [MRI] and/or severe infection)
and consisted of serial clinical evaluations at 3, 6, 12, and
24months of age. Neurological assessment was performed
according to the Amiel-Tyson evaluation. Moreover, the
Griffiths Mental Development Scale III [21] was performed
to assess the rate of development at 6, 12, and 24months.
Statistical analysis
Analyses were performed using Medcalc version 9.3.0.0
for Windows. Continuous variables were expressed as
mean ± SD or median and range; categorical data were
expressed as numbers (percentages). Student’s t-test and
Levene’s test for assessing homoscedasticity or the Mann-
Whitney rank sum test were used to compare continuous
variables, whereas the μ2 test or 2-tailed Fisher’s exact test
was used to compare categorical variables between groups.
All p values refer to 2-tailed tests of significance; p < 0.05
was considered significant.
Results
Characteristics of the population and epidemiological
data
Figure 1 shows the number of positive samples in blood
or CSF and the final diagnosis in the entire population.
There were 68 EV-PCR-positive samples among 964
tested. Most samples were obtained from CSF. Among
878 CSF samples, 62 (7.1%) were EV positive.
Samples belonged to 61 children (boys, n = 35; girls,
n = 26), of which 7 (11.5%) were admitted to the NICU,
and 54 (88.5%) were admitted to the Pediatric Unit. Most
cases had aseptic meningitis (cases aged less than 90 days:
n = 39), a few had encephalitis (aged less than 90 days: n =
4). Lumbar puncture could not be performed in 1 infant
aged less than 90 days and his illness was therefore
classified as “unspecific febrile illness”. Age at presentation
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of EV infections ranged from 2 days to 9 years. Forty-
seven of 61 (77.0%) presented within age 1 year (of
which 44 were under 90 days). The remaining 14
(23.0%) presented after age 1 year. All 4 cases of severe
EV infection were aged less than 2 weeks. Figure 2a de-
tails cases of EV infection during the 12-year study and
Fig. 2b details month of presentation, according to age.
There was a wide fluctuation in the annual number of
cases during the study, and in some years no cases
occurred among older children. Most cases had a sea-
sonal pattern and presented during summer, with a
peak in June–July.
Mode of delivery and mode of feeding among infants
aged 0 to 90 days
Most infants were born full-term (n = 37, 84.1%), after an
uncomplicated pregnancy and delivery (n = 36, 81,8%). His-
tory of concomitant upper respiratory tract infection among
Fig. 1 Virological samples, patients and diagnoses. CSF, cerebrospinal fluid; PCR, polymerase chain reaction
Fig. 2 Yearly (a) and monthly (b) distribution of enteroviral infections according to age at presentation
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family members was reported in 10 cases (22.7%). Median
5-min Apgar score was 10 (range 8–10). Seven (15.9%) were
born preterm (median gestational age 35weeks, range 31–
36). Median birth weight was 3205 g (IQR 2870-3683) and
median gestational age was 39weeks (IQR 38–40). Most
cases were exclusively breastfed (n = 23, 52.3%).
Clinical characterization
Among infants aged 0 to 90 days, severe cases were more
likely to be younger at presentation than non-severe cases
(median age 6.2 vs 26.3 days, p = 0.003). Clinical findings
at presentation and during the course of the disease are
detailed in Table 1 according to age [21].
Presentation with fever, higher median temperature, and
irritability were significantly more common among infants
aged less than 90 days. During the course of the disease, the
peak temperature was significantly higher among infants
aged less than 90 days, whereas gastrointestinal symptoms
were more common in the older population. Cutaneous
rash (characterized by small, erythematous macular or
maculopapular lesions), tachycardia and capillary refill
time > 2 s did not differ between the 2 age groups.
Laboratory tests, instrumental data
Blood tests and CSF parameters according to age [16, 17, 23]
are detailed in Table 2.
CSF pleocytosis (with wide variation in cell count) and
increased WBC count were significantly more common
among children older than 90 days, whereas a low WBC
count was more common among younger patients.
At presentation, C-reactive protein levels were mostly
within a normal range or mildly raised, but a few cases
(< 10% of children) had levels over 5 mg/dL. During the
course of the disease, C-reactive protein levels increased
to over 5 mg/dL in 18% of the entire population, without
significant differences between the 2 age groups (data
not shown).
Bilirubin levels were only assessed in younger infants.
Most levels were within a normal range, but levels were
markedly raised in 2 cases with severe infection (22 and
17mg/dl respectively).
Platelet count and alanine transaminase levels were
within normal range in most children. A few cases had
elevated CSF protein or low CSF glucose levels.
Table 3 details heart and brain investigations. Most in-
fants younger than 90 days underwent ultrasound study;
brain MRI or computed tomography was only performed
in a few children. Brain lesions were documented in 3 of 4
severely infected newborns who underwent MRI.
Therapies and outcome
Median duration of antibiotic therapy was calculated by
excluding all children with concomitant bacterial urinary
tract infection (n = 6). Median was 6 days for infants
aged less than 90 days (interquartile range [IQR] 5.5–8.0
range 3–13 days; μ 5 days, n = 27) and 7 days for infants
aged more than 90 days (IQR 5.0–7.0, range 3–9 days; ≥
5 days, n = 10). A few infants were given antiepileptic
drugs (n = 3), underwent mechanical ventilation (n = 2),
or catecholamine support (n = 1). One newborn under-
went extracorporeal membrane oxygenation. No deaths









Fever, n (%) 42 (68.9) 36 (81.8) 6 (37.5) < 0.01
Temperature, median (IQR) 38 (37.4–38.2) 38 (37.7–38.3) 37.4 (37.2–37.8) < 0.01
Irritability, n (%) 29 (47.5) 26 (59.1) 3 (17.6) < 0.01
Poor feeding, n (%) 18 (29.5) 14 (31.8) 4 (23.5) 0.74
Capillary refill time > 2″, n (%) 17 (27.9) 15 (34.1) 2 (11.8) 0.15
Tachycardia, n a 23 (37.7) 14 (31.8) 9 (52.9) 0.22
Convulsions, n (%) 3 (4.9) 3 (6.8) 0 0.65
During the course of the disease
Fever, n (%) 58 (95.1) 41 (93.2) 17 (100) 0.66
Duration (days), median (IQR) 2 (1–3) 2 (2–4) 2 (1–2) 0.05
Peak temperature (°C), median (IQR) 38.5 (38–39) 38.6 (38.2–39) 38.2 (38–38.5) 0.02
Gastrointestinal symptomsb, n (%) 27 (44.3) 13 (29.5) 14 (82.3) < 0.01
Rash, n (%) 13 (21.3) 12 (27.3) 1 (5.9) 0.14
NA Not assessable
a Normal values according to age reported in reference [22]
b One or more episodes of diarrhea and/or vomiting
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WBC count, (/μL), median (IQR) a 10,550 (6900-13,225) 0 9110 (6508-11,568) 0 12,010 (10,578-15,680) 0 NC
Raised WBC count, n (%) 10 (16.4) 0 1 (2.3) 0 9 (52.9) 0 < 0.01
Low WBC count, n (%) 16 (26.2) 0 16 (36.4) 0 0 0 0.01
CRP (mg/dL), median (IQR) b 0.81 (0.10–1.40) 6 0.81 (0.30–1.38) 6 0.91 (0.10–2.85) 0 0.60
CRP > 1 mg/dL, n (%) 24 (43.6) 16 (42.1) 8 (47.1) 0.60
CRP > 5mg/dL, n (%) c 4 (7.3) 2 (5.3) 2 (11.8) 0.66
PLT (thous/μL), median (IQR) a 305 (250–380) 0 309 (244–392) 0 293 (267–345) 0 0.65
Low PLT count, n (%) 1 (1.6) 0 1 (2.3) 0 0 0 0.62
ALT (mg/dL), median (IQR) a 22 (15–30) 2 25 (19–34) 2 14 (9–17) 0 NC
Raised ALT levels, n (%) 7 (11.9) 2 7 (16.7) 2 0 0 0.17
Total bilirubin (mg/dL), median (IQR) 3.56 (1.27–5.83) 32 3.56 (1.27–5.83) 15 – 17 NC
CSF parametersd
CSF cell count (/μL), median (IQR, range) 39 (4–250, 0–1864) 11 8 (2–185, 0–1864) 9 108 (44–339, 12–1256) 2 NC
CSF pleocytosis, n (%) 30 (60.0) 16 (45.7) 15 (100) < 0.01
CSF protein (mg/dL), median (IQR) 45.5 (33–68) 11 58.5 (39–101) 9 24 (15–42.8) 2 NC
Raised CSF protein, n (%) 15 (30.0) 13 (37.1) 2 (13.3) 0.18
CSF glucose (mg/dL), median (IQR) 46 (40–51) 5 43.5 (39–46.5) 4 58.5 (48–71) 1 NC
Low CSF glucose, n (%) 4 (7.1) 3 (7.5) 1 (6.3) 0.68
CRP C-reactive Protein, CSF Cerebrospinal fluid, Hb Haemoglobin, NA Number of cases for which data were not available; NC Not comparable; PLT Platelets; WBC
White blood cell
a Normal values according to age reported in reference [23]
b Children with concomitant urinary tract infection were excluded from the analysis
c Peak CRP > 5mg/dL during the course of the disease was present in 8 (18.2%) infants aged 0 to 90 days and 3 (17.6%) aged more than 90 days (11, 18.0% of
the total population);
d Traumatic lumbar punctures were excluded from the comparison of CSF cell count and protein levels. Pleocytosis was defined as ≥ 20/μL, 0–30 days of life; ≥
15/μL, 30–60 days of life; or ≥ 5/μL, > 60 days of life. Raised CSF protein level was > 90 mg/dL, 0–30 days of life; and > 45mg/dL, > 30 days of life. Low CSF glucose
was < 37 mg/dL, 0–30 days of life; and < 40, > 30 days of life [16, 17].







Performed, n Abnormal, n Performed, n Abnormal, n Performed, n Abnormal, n
ECG recording, n (%) 44 1 (2.3)a 17 0 61 1 (1.6)
Heart US study, n (%) 30 3 (10) b 7 0 37 3 (8.1)
Brain US study, n (%) 27 3 (11.1) c – 27 3 (11.1)
Brain MRI, n (%) 8 3 (37.5) d 1 0 9 3 (33.3)
Brain CT, n (%) – 7 0 7 0
EEG recording, n (%) 10 3 (30) 8 2 (25) 18 5 e (27.8)
CT Computed tomography, ECG Electrocardiogram, EEG Electroencephalography, MRI Magnetic resonance imaging, US Ultrasound
a Abnormal repolarization
b Low ejection fraction (n = 1), hyperechoic interventricular septum (n = 1), pericardial effusions (n = 1)
c Hyperechoic spots in the white matter and basal ganglia (n = 2), thinned brain ventricle (n = 1)
d Hyper-intense signal areas of brain white matter in T1 or T2-weighted images
e Anterior slow dysrhythmia (n = 4), status epilepticus, (n = 1), suppression burst patterns (n = 1) excess of theta rhythm (n = 1)
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were recorded. Median length of stay was 7 days (IQR
6–10). Neurodevelopmental outcome at age 2 years in
the 4 severely infected newborns with documented MRI
brain lesions was within normal range, but 1 developed
epilepsy at age 6 years.
Discussion
The current study provides detailed information regard-
ing clinical characteristics of neonatal and pediatric EV
infections from an Italian University-Teaching Hospital
over a 12-year period. No case fatalities were recorded.
In the past, EV infections have been an important cause
of mortality and morbidity in the pediatric age group,
with most symptomatic and severe cases occurring dur-
ing the first months of life. Neonatal mortality rates vary
widely (from 0 to 83%) in the literature, according to the
study population (children, neonates, severe infections)
[7, 24, 25], but lower mortality rates (0–10%) have re-
cently been reported [20, 26–29]. Myocarditis and hepa-
titis with coagulopathy are associated with greater risks
of death [19, 30].
In the present study, the total number of cases of EV in-
fection showed large fluctuations, and in some years, no
cases were recorded among older children. Consistent
with previous studies, we found that most cases had a sea-
sonal pattern with a peak during summer [1], and most
cases presented under age 90 days in full-term newborns
who had an uncomplicated pregnancy and delivery [8]. A
maternal history of viral illness is frequently (59–68%) re-
ported in previous studies [25]. Although we found that
concomitant upper respiratory tract infection among fam-
ily members was uncommon (22%), this information may
have been biased by the retrospective design of our study.
Most newborns had aseptic meningitis and a few had en-
cephalitis. This finding is consistent with large epidemio-
logical studies that describe EV as a primary cause of viral
meningitis (48–95%) in high-income settings [31, 32]. In the
current study, approximately 7% of CSF samples collected
because of clinical suspicion were confirmed EV positive.
The earlier the age at presentation, the greater the sever-
ity of disease; in fact, all severe cases occurred within age
2 weeks. This finding is consistent with previous literature
[7, 8]. Furthermore, we compared clinical findings be-
tween infants younger and older than 90 days. Fever was
common in both populations, and seizures and cutaneous
rashes were prominent among younger children, whereas
gastrointestinal symptoms and nuchal rigidity were pre-
dominant among older ones.
Although limits of CSF pleocytosis (defined according to
age) were different, infants aged less than 90 days were
more likely to present with a lower WBC count and less
likely to present with CSF pleocytosis. Consistent with pre-
vious studies [30], total bilirubin levels were significantly
higher in more severe EV infections, although this finding
would be related to the higher bilirubin levels at younger
ages rather than the severity of the disease. Only 5% of
children had seizures requiring antiepileptic treatment. All
children without concomitant bacterial infection underwent
antibiotic therapy that lasted 5 or more days in approxi-
mately 2/3 of cases. C-reactive protein levels increased in
only a few cases and could not account for the prolonged
antibiotic treatments, since more recent literature suggests
discontinuing therapy when EV infection is confirmed [33].
This study has a number of limitations. First, the retro-
spective design may have biased some information. Fur-
thermore, we could not associate clinical findings with
molecular / genomic data. Indeed, the medical literature
reports variations in the clinical presentation and CSF find-
ings with different EV subtypes. Furthermore, the diagnosis
of EV infection did not include PCR on stool and respira-
tory specimens (as reported in more recent studies by
others) [34]. MRI represents the most sensitive imaging
technique in patients with severe infection and focal neuro-
logic signs, and is advisable in the presence of profound
lethargy or neurologic deterioration [35]. In the current
study, most but not all children with abnormal neurological
signs (i.e. hypotonia, abnormal EEG) underwent MRI;
therefore, encephalitis and severe disease may have been to
some extent underestimated. Finally, only a few children
(mostly those with severe infection, convulsions, or myo-
carditis) underwent neurodevelopmental follow-up. Early
studies reported white matter abnormalities and long-term
impairment (such as neurodevelopmental delay, cerebral
palsy, and epilepsy), in surviving neonates after NICU
admission due to EV infection. During the 80s, Wilfert [36]
showed that receptive language function was significantly
diminished in 9 children with EV infection compared to
that in 9 controls. More recently, Verboon-Maciolek [35]
studied 6 infants aged less than 60 days with meningo-
encephalitis presenting with seizure or hypotonia; 2 of 6
developed cerebral palsy and epilepsy. Among 17 con-
firmed EV encephalitis cases, Pillai [37] reported abnormal
outcomes in 8 cases, of which 3 developed epilepsy. How-
ever, there is a lack of large studies detailing the neurodeve-
lopmental outcome of EV infections.
Conclusions
We reviewed cases of EV infections from an Italian
pediatric cohort and we confirmed that EV represent a
relevant cause of illness and CNS infection. Clinical char-
acteristics may vary according to age of presentation, but
more severe infections occur among infants aged less than
90 days. Our findings suggest that neurodevelopmental fol-
low-up should be planned after CNS EV infections.
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